NEW YORK, April 15, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of three key executives in high priority strategic roles integral to the preparation for the potential Zerenex™ (ferric citrate coordination complex) product launch. The Company's New Drug Application for Zerenex™, an oral, ferric iron-based compound, is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) target goal date of June 7, 2014.
Help employers find you! Check out all the jobs and post your resume.
